A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)

16165MK-2870-011-NCT06841354OpenA Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)MK-2870-011NCT06841354IndustrialAdultTreatmentIIIOtherKurian, ShwetaMedStar Health and GUMC; Medstar Franklin Square Medical Center : Amy Avergas; Medstar Good Samaritan Hospital; Medstar Montgomery Medical Center; Medstar Washington Hospital CenterBreastOncology GroupMHRI Oncology Baltimore6959Amy AvergasAmy AvergasAmy.m.avergas@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>